logo-loader

ImmunoPrecise Antibodies hires LightPath Capital as key partner in its financing strategy

Last updated: 14:01 18 Jan 2018 EST, First published: 09:01 18 Jan 2018 EST

1516302249_agreement-7
LightPath will act as the group's financial adviser and placement agent

ImmunoPrecise Antibodies Ltd (CVE:IPA, OTC PINK:IPATF) has hired San Francisco based LightPath Capital Inc to help in its bid to raise up to $20mln with institutional investors to aid its acquisition strategy.

The latter will act as the group's financial adviser and placement agent.

This is also a strategic first step in positioning the company to pursue a listing on the Nasdaq within the next year, said Immunoprecise.

"In engaging LightPath based in one of the world's largest biotech hubs, IPA is proceeding with financing of its strategic acquisition activities and engaging strategic partners globally," said Dr James Kuo, chairman and interim president Immunoprecise.

Ron E. Foy, of LightPath's San Francisco office, added: "We are very pleased to have the opportunity to work with Immunoprecise on this assignment, and we believe that the company's growth strategy is well-timed and that Immunoprecise provides a significant rollout strategy opportunity in the antibody discovery process space in which humanized antibody technologies will drive higher margins by arbitraging Europe with America's health care sector."

ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

on 09/30/2020